4D MOLECULAR THERAPEUTICS IN (FDMT) Stock News

NASDAQ:FDMT - Nasdaq - US35104E1001 - Common Stock - Currency: USD

4.285 +0.13 (+3%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

FDMT Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

5 days ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

13 days ago - By: Benzinga

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

14 days ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

14 days ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

5 months ago - By: Benzinga

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

2 months ago - By: Zacks Investment Research - Mentions: VRCA

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

2 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

3 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

3 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

3 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

3 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces New Employment Inducement Grants

4 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

4 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

4 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

4 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

5 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

5 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

5 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

5 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences

5 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

5 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

5 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

5 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

6 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

6 months ago - By: 4D Molecular Therapeutics, Inc.

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

6 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

6 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT